Graph Therapeutics Secures $5M to Advance AI-Driven Precision Therapies

Biotechnology company Graph Therapeutics has closed a $5 million funding round. It was led by Paris-based venture capital firm Daphni, which joins existing investors SquareOne, Merantix Capital, and NAVEC Investment Management.

Graph Therapeutics: Total funding exceeds 10 million

In addition, the company receives non-dilutive funding from the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice (AWS). Including this funding, Graph Therapeutics’ total financing to date amounts to more than ten million US dollars.

Graph Therapeutics is developing an AI-powered platform for researching new drugs against inflammatory and immune-mediated diseases. With the new capital, the company plans to further expand its own pipeline of drug candidates.

At the same time, thanks to its technology already validated in clinically relevant models, Graph Therapeutics believes it is well-positioned to enter into strategic partnerships and make its platform available to other pharmaceutical and biotech companies through licensing agreements. Daphni’s investment is expected to accelerate this growth trajectory and drive the development of new precision therapies based on the analysis of real patient cells.

Founding team with experience from other biotech sectors

Graph Therapeutics utilizes an AI-powered platform that combines data from living patient cells with advanced analytical methods to better understand the causes of immune system disorders. The founding team brings experience from the biotech company Allcyte , which was later acquired by Exscientia. Graph’s goal is to identify new drug targets and biomarkers, thereby accelerating the development of more precise therapies for inflammatory and immune-mediated diseases.

“Our platform has reached a critical turning point. We are now gaining biologically relevant insights that directly inform our own drug development programs,” says Gregory Vladimer, co-founder and CEO of Graph Therapeutics. “Daphni’s confidence in our approach sends a powerful signal as we scale investments in our drug programs. With their support and that of our existing investors, we have both the necessary backing and the drive to develop precision medicines for inflammatory and immune-mediated diseases and to demonstrate to the industry that systematically deciphering immune dysfunctions in real patient cells reveals the true causes of disease.”

For Sofia Dahoune, partner at Daphni, Graph exemplifies the next generation of TechBio companies: “A company where profound technological innovation is inextricably linked to excellent research and development, and which is led by a team with proven expertise in precision medicine. The complexity of immune-mediated diseases demands precisely such an integrated approach.”

__

(Featured image by Edward Jenner via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in brutkasten. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.